At a glance

1. What is it, chemically speaking?

Phenylpiracetam is easiest to understand as piracetam with a “phenyl ring” attached.

Piracetam is the original “nootropic,” synthesized in the 1960s in Romania by chemist Corneliu Giurgea, who also coined the term nootropic (from Greek roots roughly meaning “toward the mind”). Piracetam’s effects are famously subtle.

A phenyl ring is a small six-carbon loop — an extremely common piece of molecular decoration in chemistry.

Attach that ring to piracetam at one position and you get phenylpiracetam, which behaves quite differently: it becomes noticeably stimulating, on top of the mild cognitive-support qualities associated with racetams.

Two structural points are worth understanding right away:

• Point 1 — It is a “racetam.” Racetams share a common ring (a pyrrolidone) plus an acetamide side group. They are not all alike — piracetam is a gentle nootropic, phenylpiracetam is a stimulant-nootropic hybrid, and levetiracetam is a widely used epilepsy drug. “Racetam” describes a chemical family, not a single effect.
• Point 2 — It also looks like a phenethylamine. Hidden inside phenylpiracetam’s structure is a fragment that resembles the phenethylamine family, a broad class of molecules that includes many stimulants. This dual identity helps explain why phenylpiracetam doesn’t feel like a typical quiet racetam.

A note on a common internet claim: one early review described carphedon as essentially “piracetam plus amphetamine.” This is a popular but chemically misleading simplification. Phenylpiracetam is piracetam plus a phenyl ring; the amphetamine-like resemblance is structural and partial, not a recipe. Its pharmacology is also far milder than amphetamine’s, as we’ll see.

The molecule exists as a 50/50 mixture of mirror-image forms — an R and an S version — a topic covered in detail in the “Enantiomers” section. What you may have noticed already: the standard product is always this mixture, never one pure form.

2. The many names of one molecule

Phenylpiracetam has accumulated more names than most drugs, and knowing them helps when reading about it:

• Carphedon (carphedone) — the older name most often seen in doping literature and early papers.
• Phenotropil / Fenotropil — the first major Russian brand name (Valenta), launched around 2005.
• Fonturacetam — the current international nonproprietary name (INN), assigned to the standard mixture (racemate).
• Actitropil — the current Russian brand marketed by Pharmstandard, and the name used in most recent clinical research.
• MRZ-9547 / MRZ-9546 — investigational code names for the pure R and S enantiomers, respectively, studied in Europe.

3. Born in space: the real history

The space-program origin is one of the few nootropic legends that is essentially accurate.

In the 1980s, researchers at the Soviet Union’s Institute of Biomedical Problems in Moscow were seeking compounds that could help cosmonauts maintain mental and physical performance under extreme conditions — chronic stress, disrupted sleep, cold, and prolonged confinement. The existing options were unsuitable: amphetamines and related drugs cause agitation, cardiovascular strain, and dependence, all unacceptable in space.

The search was led by psychopharmacologist Valentina Ivanovna Akhapkina and colleagues. The resulting compound — first described in the scientific literature around 1983 (with an earlier synthesis reported in 1980) — was phenylpiracetam. It was adopted for use by cosmonauts and, according to first-hand accounts, stocked in spacecraft emergency medical kits.

One account is unusually direct. Pilot-cosmonaut Aleksandr Serebrov, who spent 197 days aboard the Mir space station, described being issued the drug and said it acted as “the equalizer of the whole organism,” smoothing out the impulsiveness and irritability that prolonged spaceflight stress can produce.

From there, the molecule made three notable journeys:

• Into Soviet/Russian military and space medicine, as a performance- and resilience-enhancing agent;
• Into civilian clinical practice, approved in Russia in 2003 for a range of conditions (fatigue and asthenia, cerebrovascular insufficiency, post-stroke and post-brain-injury recovery, depression, apathy, attention, and memory complaints, among others);
• Into sport and then onto the banned list, where it became one of the earliest “nootropic” doping cases (more in Section 10).

In the West, interest resurfaced in the 2010s: the pure R-enantiomer (MRZ-9547) was investigated by the German company Merz as a potential treatment for fatigue in Parkinson’s disease. No recent development has been reported, but that work produced much of what we now know about the molecule’s mechanism.

4. How does it work in the brain?

For decades, the mechanism was simply unknown — phenylpiracetam was a drug whose effects people could measure better than its targets. That changed around 2014, but the picture is still incomplete. Today researchers describe several distinct “levers,” some better established than others.

Lever 1 — The dopamine transporter (DAT): the “recycling crew” slowed down

Dopamine is a chemical messenger associated with motivation, reward, drive, and movement. After a neuron releases dopamine, dedicated transporter proteins vacuum it back up to end the signal. A dopamine reuptake inhibitor partially blocks that vacuum, letting dopamine linger a little longer in the gaps between neurons.

Phenylpiracetam is now understood to be a relatively weak, “atypical” dopamine reuptake inhibitor. The word atypical matters: it doesn’t flood the brain with dopamine the way amphetamine does, and it doesn’t have the same abuse or stimulant profile. Its closest conceptual relatives in this class are drugs like modafinil, mesocarb (Sydnocarb), and solriamfetol — wakefulness/motivation agents that raise dopamine gently.

In laboratory assays, the R-enantiomer inhibits dopamine uptake with modest potency (IC₅₀ values in the low-to-mid micromolar range), and microdialysis experiments confirm it produces a moderate increase in extracellular dopamine in the striatum of rats. This is likely the main source of the “switched-on” feeling users describe.

Lever 2 — Norepinephrine: a modest nudge toward wakefulness

Norepinephrine is closely related to adrenaline and promotes alertness and readiness. The R-enantiomer also binds the norepinephrine transporter (NET), but with roughly 11-fold lower affinity than its dopamine binding — making it a mild “dual” reuptake inhibitor weighted toward dopamine. The S-enantiomer, notably, appears to leave NET largely alone.

Lever 3 — Nicotinic acetylcholine receptors: attention’s “volume dial”

Nicotinic receptors are named because nicotine happens to bind them, but in normal life they respond to the brain’s own chemical, acetylcholine, which is centrally involved in attention and memory. Phenylpiracetam binds one specific subtype — the α4β2 nicotinic receptor — in the cerebral cortex. This is thought to contribute to effects on attention.

A valuable negative finding accompanies this: phenylpiracetam does not strongly bind the classic dopamine D₁/D₂/D₃ receptors, the serotonin 5-HT₂ receptor, or GABA-A/GABA-B receptors. In other words, it is better described as a modulator of existing signaling than as an on/off switch at any single receptor.

Lever 4 — Glutamate and AMPA receptors: the “learning dial”

Glutamate is the brain’s main excitatory neurotransmitter — its central “gas pedal.” Within glutamate signaling, AMPA receptors act as gain controls on learning circuits. Racetams, including phenylpiracetam, are described as AMPA-receptor modulators that may slightly strengthen certain signals. This is where the “memory enhancement” claim lives, and it is among the least firmly established parts of the story.

Beyond the classic four: broader effects under study

Recent reviews (notably a 2024 analysis by Gromova and Torshin) catalog a wider spectrum of reported activities in experimental and clinical work:

• Anti-hypoxic action — helping brain tissue tolerate low oxygen;
• Mitochondrial protection — supporting the energy factories inside cells;
• Antioxidant and anti-inflammatory activity — demonstrated for R-phenylpiracetam in mouse models of inflammation;
• Anticonvulsant effects — distinct from plain piracetam in some early work;
• Mild adaptogenic properties — improving tolerance to cold and physical stress.

An honest summary: there is no single “this is how it works” answer. Instead, phenylpiracetam appears to deliver a coordinated, small-amplitude nudge across dopamine, norepinephrine, acetylcholine, and glutamate systems — which fits both its stimulant-like feel and its racetam-like cognitive effects.

Analogy: Think of the brain as a busy city. Dopamine is the motivation to start a project; norepinephrine is the street lighting that keeps you awake; acetylcholine is the attention that keeps your eyes on the road; glutamate is the traffic flow itself. Phenylpiracetam gives several of these systems a gentle, simultaneous nudge rather than any one dramatic push.

5. What does the evidence actually show?

Human evidence: asthenia (pathological fatigue) is the best-studied use

The most important recent human data set is a 2025 systematic review and meta-analysis by Devlikamova and Safina, which pooled 11 Russian clinical studies including 549 patients treated with 200 mg/day of fonturacetam for one month.

The headline results:

• The main measure of asthenia (the MFI-20 fatigue scale) fell by an average of 16.3 points after one month (statistically significant).
• Researchers also reported improvements in emotional state, sleep, cognitive function, and quality of life, with high patient satisfaction.
• Side effects occurred in about 5.5% of patients — mostly transient, resolving within a week of continued treatment.
• No withdrawal syndrome was identified in any included study.

Asthenia — a medical term for persistent fatigue, weakness, and reduced physical and mental performance — is precisely the condition this drug was built for, and it is where the human evidence is strongest.

A second large dataset is the non-interventional TRIUMPH program: 1,170 patients with chronic cerebral ischemia (reduced brain blood flow) treated with 100 mg/day for two to three months, reporting significant and sustained reductions in asthenia.

Additional smaller studies — mostly in Russian journals — have reported benefits in:

• Recovery after stroke and after traumatic brain injury;
• Vascular encephalopathy and chronic cerebral ischemia;
• Epilepsy as an add-on therapy (leveraging the anticonvulsant effect);
• Parkinson’s disease as add-on “neurometabolic” therapy;
• Glaucoma, and post-COVID fatigue.

Animal and cellular evidence

Laboratory studies report a consistent, if preliminary, set of effects:

• Memory: R-phenylpiracetam enhances memory in passive-avoidance tests (at low doses), and phenylpiracetam reverses scopolamine-induced amnesia in rats while normalizing dopamine D₁, nicotinic, and benzodiazepine receptor densities.
• Motivation: In effort-based tasks, R-phenylpiracetam (MRZ-9547) increased how hard rats would work for food — in one study, more than methylphenidate or amphetamine at certain doses. This is the experimental foundation for claims about “motivation” enhancement, and it’s a promising lead for fatigue disorders — but it is a single-model finding in rodents.
• Neuroprotection: In models of cerebral ischemia (interrupted brain blood flow), phenylpiracetam reduced neurological deficits, preserved memory and locomotion, and improved survival, outperforming piracetam in some measures.
• Anti-inflammatory/neuroprotective: R-phenylpiracetam reduced neuroinflammation in mouse models (2020).
• Metabolic effects: The S-enantiomer, as a selective DAT inhibitor, reduced body-weight gain and improved glucose handling in obese rodents without increasing movement — raising intriguing questions about whether a dopamine transporter inhibitor can have “metabolic” effects separate from “stimulant” effects. Computer-assisted analyses (chemoreactomic methods) have proposed additional receptor-level explanations for this, but these are predictions pending experimental confirmation.

The standing rule with animal data applies here in full: rodent findings do not automatically transfer to humans.

Physical performance and cold resistance

Consistent with its origins, research from the 1980s onward has described improved physical work capacity and cold tolerance. This is the characteristic most clearly tied to its space-program use case, and the one that eventually made it a sports-doping concern.

6. Enantiomers: the left-handed and right-handed versions

This is one of the most scientifically interesting aspects of the compound, and one users rarely appreciate.

Like many drugs, phenylpiracetam has mirror-image forms — an R form and an S form — and the standard medicine is a 50/50 mix of both. Nature often treats the two shapes differently, like a left and right glove.

Here is what research currently suggests:

Three practical takeaways:

• The stimulant and memory side lives mostly in the R form; the S form is more “quiet” and may even dilute some of R’s effects in certain tasks.
• Because ordinary products always contain both forms, “100 mg of phenylpiracetam” is less precise than it sounds — it means roughly 50 mg of R plus 50 mg of S.
• The enantiomers have been actively studied in the West as distinct drug candidates, which is uncommon for something sold casually online as a “supplement.”

7. What happens to it in the body? (Pharmacokinetics)

Pharmacokinetics is the journey a drug takes through the body. Phenylpiracetam’s journey is unusually clean.

• Absorption: Taken by mouth, it is absorbed essentially completely (bioavailability ≈ 100%), with effects beginning in under an hour and peak blood levels around one hour.
• Distribution: It crosses the blood–brain barrier effectively — a key part of its design.
• Metabolism: Remarkably, it is essentially not metabolized — the liver doesn’t break it down into active or inactive chunks the way it does most drugs.
• Elimination: It leaves the body unchanged — roughly 40% in urine and 60% in bile and sweat, with a short half-life of 3–5 hours in humans.

Two implications follow. First, because it is excreted intact, it is easy to detect in urine — which is exactly why it was caught quickly in doping controls. Second, the short half-life explains the practical dosing pattern: effects are relatively brief, and daily use (often dosed more than once) is how people sustain them.

One caveat from the literature itself: formal human pharmacokinetic studies remain unpublished, so these figures come from drug monographs and reviews rather than a large modern PK dataset. In rodents, the half-life is even shorter (2.5–3 hours).

8. What do people use it for, and what is it reported to feel like?

Setting aside the medical uses above, phenylpiracetam’s popular reputation rests on self-reported effects. It is worth labeling these distinctly: they are anecdotal, not clinical evidence.

Commonly reported experiences include:

• A clean, sustained wakefulness often compared to caffeine but described as smoother — less tremors and anxiety;
• Increased motivation and a lower barrier to starting difficult work;
• A mild mood lift and reduced sense of mental fatigue;
• Subjective improvement in focus, verbal fluency, and stamina;
• A desire to dose in the morning or early afternoon, because of sleep disruption.

Consistent with its pharmacology, reports describe a false “honeymoon”: the energizing effect is often strongest over the first few uses and then fades with daily, repeated dosing. This is what “tolerance” means in everyday terms, and it has not been rigorously characterized in published trials — but it is one of the most consistent themes in user reports and is biologically plausible for a dopamine-reuptake mechanism.

A neutral framing is important here: placebo and expectation are powerful, especially for a substance carrying a “cosmonaut drug” legend, and self-reports from unregulated products cannot confirm what the molecule itself did.

9. Side effects, contraindications, and safety unknowns

Known side effects (from product monographs and clinical reports):

• Insomnia and sleep disturbance — the most characteristic issue, especially with late-day dosing;
• Psychomotor agitation, restlessness, or feeling “wired”;
• Flushing and a sensation of warmth;
• Increased blood pressure and/or heart rate;
• Headache;
• Reduced appetite (an “anorexigenic” effect noted especially with extended use).

Formal contraindications include individual intolerance, and the available literature lists caution in the groups one would expect for any stimulant-like drug: people with significant cardiovascular disease, uncontrolled hypertension, severe anxiety or psychotic disorders, significant liver or kidney impairment, and — because of absent safety data — pregnancy and breastfeeding (pregnancy category: unknown).

What’s reassuring (with limits):

• Acute toxicity is low in animals: the oral LD₅₀ (the dose lethal to half of a test population) in mice is about 6,800 mg/kg — orders of magnitude above any human dose.
• Human overdose has not been reported in the literature.
• In the pooled clinical data, side effects were uncommon (≈5.5%), mostly transient, and no withdrawal syndrome was observed.

What’s uncertain:

• Long-term human safety data are essentially absent. The drug is decades old in Russia, but there is no large, modern, long-term safety surveillance comparable to what Western regulators require.
• Tolerance and escalation are widely reported by users but poorly studied scientifically.
• Interactions with other drugs — other stimulants, dopaminergic agents, antidepressants, or MAO inhibitors — are largely unstudied.